Search

Displaying results 5071 - 5080 of 10000 in total
  1. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.

  2. Drug

    Bioymifi

    go.drugbank.com/drugs/DB17493
    Experimental

    Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent. … Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic.

  3. Drug

    SRP 299

    go.drugbank.com/drugs/DB05440
    Experimental

    SRP 299 is a preparation of killed Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and in treating eczema, itching and inflammation. … A specific subset of serotonergic neurons in the interfascicular part of the dorsal raphe nucleus (DRI) is believed to be involved, based on studies with mice.

  4. Drug

    Iratumumab

    go.drugbank.com/drugs/DB05550
    Investigational

    Molecular weight is approximately 170,000 daltons. In phase I/II clinical trials for treatment of CD30+ lymphomas.

  5. Drug

    Ferrous asparto glycinate

    go.drugbank.com/drugs/DB11169
    Approved

    Ferrous asparto glycinate is an iron-amino acid chelate. It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.

  6. Drug

    XP12B

    go.drugbank.com/drugs/DB04928
    Investigational

    XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.

  7. Drug

    SNX-5422

    go.drugbank.com/drugs/DB06070
    Investigational

    SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. … As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.

  8. Drug

    ACE393

    go.drugbank.com/drugs/DB05071
    Investigational

    ACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world.

  9. Drug

    Berberine

    go.drugbank.com/drugs/DB04115
    ApprovedInvestigationalWithdrawn

    An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. … It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.

  10. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause